Trials / Terminated

TerminatedNCT01355003

GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)

Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) Post Marketing Surveillance Protocol

Status: Terminated
Phase: —
Study type: Observational
Enrollment: 1,080 (actual)

Sponsor: Merck Sharp & Dohme LLC · Industry
Sex: All
Age: 9 Years – 46 Years
Healthy volunteers: Accepted

Summary

This study will collect safety information on the use of GARDASIL™ in the Philippines.

Conditions

Papillomavirus Infections

Timeline

Start date: 2008-02-01
Primary completion: 2010-06-01
Completion: 2010-06-01
First posted: 2011-05-17
Last updated: 2015-08-13

Source: ClinicalTrials.gov record NCT01355003. Inclusion in this directory is not an endorsement.

GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077) (NCT01355003) · Clinical Trials Directory